Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Stinton, Laura M ^a   Myers, Robert P ^a   Coffin, Carla S ^a   Fritzler, Marvin J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANTIBODY; AUTOANTIBODY; CYTIDINE TRIPHOSPHATE SYNTHASE 1 ANTIBODY; INOSINE MONOPHOSPHATE DEHYDROGENASE 2 ANTIBODY; INTERFERON; MYC PROTEIN; RIBAVIRIN; RODS AND RINGS ANTIBODY; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGENICITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTEIN MICROARRAY;

ANTIVIRAL AGENTS; AUTOANTIBODIES; CARBON-NITROGEN LIGASES; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMP DEHYDROGENASE; INCLUSION BODIES; INTERFERONS; LIVER CIRRHOSIS, BILIARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; STAINING AND LABELING;

EID: 84875067863     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-50     Document Type: Article

References (61)

1. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011, 364:2429-2438. 10.1056/NEJMcp1006613, 21696309.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52. 10.1056/NEJM200107053450107, 11439948.
3. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007, 39:2-17. 10.1016/j.dld.2006.06.008, 16884964.
4. Paroli M, Iannucci G, Accapezzato D. Hepatitis C virus infection and autoimmune diseases. Int J Gen Med 2012, 5:903-907. 3484639, 23118549.
5. Ram M, Anaya JM, Barzilai O, Izhaky D, Porat Katz BS, Blank M. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev 2008, 7:621-625. 10.1016/j.autrev.2008.06.008, 18603025.
6. Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001, 48:378-383. 10.1136/gut.48.3.378, 1760154, 11171829.
7. Preziati D, La RL, Covini G, Marcelli R, Rescalli S, Persani L. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995, 132:587-593. 10.1530/eje.0.1320587, 7749499.
8. Mauss S, Berger F, Schober A, Moog G, Heyne R, John C. Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome. J Viral Hepatol 2013, 20:e72-e77.
9. Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis. PLoS One 2013, 4:e55364.
10. Fabbri C, Jaboli MF, Giovanelli S, Azzaroli F, Pezzoli A, Accogli E. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003, 9:1487-1490.
11. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995, 21:613-619.
12. Abuaf N, Lunel F, Giral P, Borotto E, Laperche S, Poupon R. Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol 1993, 18:359-364. 10.1016/S0168-8278(05)80281-8, 8228130.
13. Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le CY. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992, 16:630-636. 10.1002/hep.1840160304, 1380479.
14. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992, 103:1290-1295.
15. Zauli D, Cassani F, Bianchi FB. Auto-antibodies in hepatitis C. Biomed Pharmacother 1999, 53:234-241. 10.1016/S0753-3322(99)80094-8, 10424245.
16. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de recherche en medecine interne et maladies infectieuses sur le virus de l'Hepatite C. Medicine (Baltimore) 2000, 79:47-56.
17. Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005, 40:501-507. 10.1086/427285, 15712070.
18. Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van Thiel DH. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases. Hepatogastroenterology 1997, 44:417-425.
19. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997, 26:561-566. 10.1002/hep.510260305, 9303483.
20. Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999, 45:435-441. 10.1136/gut.45.3.435, 1727651, 10446115.
21. Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C, Lorenzen J. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004, 4:4. 10.1186/1471-2334-4-4, 373450, 15040810.
22. Gatselis NK, Georgiadou SP, Koukoulis GK, Tassopoulos N, Zachou K, Liaskos C. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther 2006, 24:1563-1573. 10.1111/j.1365-2036.2006.03165.x, 17094775.
23. Hsieh MY, Dai CY, Lee LP, Huang JF, Tsai WC, Hou NJ. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008, 61:333-337.
24. Luo JC, Hwang SJ, Li CP, Lu RH, Chan CY, Wu JC. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gastroenterol Hepatol 1998, 13:475-479. 10.1111/j.1440-1746.1998.tb00671.x, 9641643.
25. Stroffolini T, Colloredo G, Gaeta GB, Sonzogni A, Angeletti S, Marignani M. Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An italian multicentre survey. J Viral Hepat 2004, 11:257-262. 10.1111/j.1365-2893.2004.00489.x, 15117328.
26. Narciso-Schiavon JL, Freire FC, Suarez MM, Ferrari MV, Scanhola GQ, Schiavon LL. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?. Eur J Gastroenterol Hepatol 2009, 21:440-446. 10.1097/MEG.0b013e3283089392, 19382301.
27. Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 2004, 11:459-464. 10.1111/j.1365-2893.2004.00530.x, 15357653.
28. Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat 2009, 16:325-331. 10.1111/j.1365-2893.2008.01035.x, 19302340.
29. Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000, 33:791-798. 10.1016/S0168-8278(00)80312-8, 11097489.
30. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999, 30:376-382. 10.1016/S0168-8278(99)80093-2, 10190717.
31. Noda K, Enomoto N, Arai K, Masuda E, Yamada Y, Suzuki K. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol 1996, 31:716-722. 10.3109/00365529609009156, 8819224.
32. Seelig HP, Appelhans H, Bauer O, Bluthner M, Hartung K, Schranz P. Autoantibodies against inosine-5′-monophosphate dehydrogenase 2-characteristics and prevalence in patients with HCV-infection. Clin Lab 2011, 57:753-765.
33. Carcamo WC, Satoh M, Kasahara H, Terada N, Hamazaki T, Chan JY. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One 2011, 6:e29690. 10.1371/journal.pone.0029690, 3248424, 22220215.
34. Covini G, Carcamo WC, Bredi E, von Muhlen CA, Colombo M, Chan EK. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther 2012, 17:805-811.
35. Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat 2012, 19:103-111. 10.1111/j.1365-2893.2011.01442.x, 21699630.
36. Stinton LM, Swain M, Myers RP, Shaheen AA, Fritzler MJ. Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol 2011, 163:147-156. 10.1111/j.1365-2249.2010.04288.x, 3043305, 21091667.
37. Fritzler MJ. Autoantibody testing: procedures and significance in systemic rheumatic diseases. Methods Achiev Exp Pathol 1986, 12:224-260.
38. Bhanji RA, Eystathioy T, Chan EK, Bloch DB, Fritzler MJ. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 2007, 125:247-256. 10.1016/j.clim.2007.07.016, 2147044, 17870671.
39. NCBI Resources Myc-associated zinc finger protein http://www.ncbi.nlm.nih.gov/protein/P56270, NCBI Resources.
40. Bossone SA, Asselin C, Patel AJ, Marcu KB. MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination. Proc Natl Acad Sci USA 1992, 89:7452-7456. 10.1073/pnas.89.16.7452, 49728, 1502157.
41. Shoshan-Barmatz V, Mizrachi D. VDAC1: from structure to cancer therapy. Front Oncol 2012, 2:164. 3516065, 23233904.
42. Arbel N, Ben-Hail D, Shoshan-Barmatz V. Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem 2012, 287:23152-23161. 10.1074/jbc.M112.345918, 22589539.
43. Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet 2012, 21:5131-5146. 10.1093/hmg/dds360, 22926141.
44. Barrick D, Ferreiro DU, Komives EA. Folding landscapes of ankyrin repeat proteins: experiments meet theory. Curr Opin Struct Biol 2008, 18:27-34. 10.1016/j.sbi.2007.12.004, 2680087, 18243686.
45. Gaudet R. A primer on ankyrin repeat function in TRP channels and beyond. Mol Biosyst 2008, 4:372-379. 10.1039/b801481g, 3006086, 18414734.
46. Bingham JB, Schroer TA. Self-regulated polymerization of the actin-related protein Arp1. Curr Biol 1999, 9:223-226. 10.1016/S0960-9822(99)80095-5, 10074429.
47. Novatchkova M, Eisenhaber F. A CH domain-containing N terminus in NuMA?. Protein Sci 2002, 11:2281-2284. 2373702, 12237450.
48. Gregorio GV, Choudhuri K, Ma Y, Pensati P, Iorio R, Grant P. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003, 133:404-413. 10.1046/j.1365-2249.2003.02229.x, 1808793, 12930368.
49. Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KM, Reichen J. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999, 190:169-176. 10.1084/jem.190.2.169, 2195568, 10432280.
50. Sutti S, Vidali M, Mombello C, Sartori M, Ingelman-Sundberg M, Albano E. Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: possible role for molecular mimicry. J Hepatol 2010, 53:431-438. 10.1016/j.jhep.2010.03.030, 20576306.
51. Maecker HT, Do MS, Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc Natl Acad Sci USA 1998, 95:2458-2462. 10.1073/pnas.95.5.2458, 19373, 9482907.
52. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
53. Fabris P, Betterle C, Floreani A, Greggio NA, De LF, Naccarato R. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992, 340:548.
54. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998, 28:514-517. 10.1016/S0168-8278(98)80328-0, 9551692.
55. Floreani A, Chiaramonte M, Greggio NA, Fabris P, De LF, Naccarato R. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. Ital J Gastroenterol Hepatol 1998, 30:71-76.
56. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995, 108:1770-1777. 10.1016/0016-5085(95)90139-6, 7768382.
57. Imagawa A, Itoh N, Hanafusa T, Waguri M, Kuwajima M, Matsuzawa Y. Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis. Diabetologia 1996, 39:126.
58. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992, 116:51-53.
59. Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Liu C, Daves M. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and italian HCV patients. J Clin Immunol 2012, October 26, EPub ahead of print.
60. Jordan-Sciutto KL, Dragich JM, Caltagarone J, Hall DJ, Bowser R. Fetal Alz-50 clone 1 (FAC1) protein interacts with the Myc-associated zinc finger protein (ZF87/MAZ) and alters its transcriptional activity. Biochemistry 2000, 39:3206-3215. 10.1021/bi992211q, 10727212.
61. Merdes A, Heald R, Samejima K, Earnshaw WC, Cleveland DW. Formation of spindle poles by dynein/dynactin-dependent transport of NuMA. J Cell Biol 2000, 149:851-862. 10.1083/jcb.149.4.851, 2174573, 10811826.